VEEV

Veeva Systems operates with an exceptional capital structure characterized by zero leverage (D/E 0.0) and a robust current ratio of 4.89, positioning the health care software provider among the most financially conservative names in enterprise SaaS. The company's market capitalization of $26.5B reflects a business model generating 75.53% gross margins and 28.44% net margins, fundamentals that systematic screening flags as significantly above sector medians for enterprise software platforms.

The valuation framework presents a nuanced picture. With a P/E ratio of 29.42 against 26.1% EPS growth, the PEG relationship indicates relative alignment between multiples and expansion rates. However, the current price of $163.85 sits 47% below the 52-week high of $310.5, a compression that occurred despite revenue advancing 16.34% year-over-year. The P/S ratio of 8.37 and P/B of 4.63 reflect premium positioning, while the beta of 0.91 demonstrates below-market volatility characteristics.

Key screening observations include:

• Return profile showing ROE of 13.41% and ROA of 11.07%, with operating margins of 28.68% indicating operational efficiency
• Book value per share of $44.05 supporting a tangible equity foundation beneath the current valuation
• Debt-free balance sheet providing financial flexibility uncommon in growth-stage technology
• Revenue momentum maintaining mid-teens expansion despite market cap contraction

The primary risk centers on valuation sensitivity, as healthcare IT multiples remain vulnerable to interest rate fluctuations and SaaS repricing cycles. Relative to peers including Waystar (WAY), Doximity (DOCS), and Health Catalyst (HCAT), Veeva's fortress balance sheet and margin structure represent differentiated financial positioning within specialized vertical software.